KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Non-cash Items (2016 - 2024)

Historic Non-cash Items for Acadia Pharmaceuticals (ACAD) over the last 13 years, with Q4 2024 value amounting to $7.0 million.

  • Acadia Pharmaceuticals' Non-cash Items fell 9230.67% to $7.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $7.0 million, marking a year-over-year decrease of 9230.67%. This contributed to the annual value of $7.0 million for FY2024, which is 9230.67% down from last year.
  • As of Q4 2024, Acadia Pharmaceuticals' Non-cash Items stood at $7.0 million, which was down 9230.67% from $91.0 million recorded in Q4 2023.
  • Acadia Pharmaceuticals' Non-cash Items' 5-year high stood at $379.2 million during Q4 2020, with a 5-year trough of $1.1 million in Q4 2022.
  • In the last 5 years, Acadia Pharmaceuticals' Non-cash Items had a median value of $16.4 million in 2021 and averaged $98.9 million.
  • Per our database at Business Quant, Acadia Pharmaceuticals' Non-cash Items plummeted by 9567.13% in 2021 and then surged by 854657.79% in 2023.
  • Acadia Pharmaceuticals' Non-cash Items (Quarter) stood at $379.2 million in 2020, then crashed by 95.67% to $16.4 million in 2021, then plummeted by 93.59% to $1.1 million in 2022, then surged by 8546.58% to $91.0 million in 2023, then tumbled by 92.31% to $7.0 million in 2024.
  • Its last three reported values are $7.0 million in Q4 2024, $91.0 million for Q4 2023, and $1.1 million during Q4 2022.